RGEN
REPLIGEN CORP
Nasdaq Biological Products, (No Diagnostic Substances) Large accelerated filer

Key Financials

Gross Profit
$60.5M
↑ 11.1%
Net Income
$48.9M
↑ 291.6%
Operating Income
$55.2M
↑ 257.1%
Revenue
$141.2M
↑ 239.4%
EPS (Diluted)
$0.86
↑ 287.0%
Total Liabilities
$843.6M
↓ 1.6%
Total Assets
$2.9B
↑ 4.2%
Cash & Equivalents
$566.0M
↓ 25.3%

Recent SEC Filings

Form Type Filed Date Link
SCHEDULE 13G/A 8/14/2026 View on SEC
425 8/4/2026 View on SEC
SCHEDULE 13G 7/31/2026 View on SEC
10-Q 7/29/2026 View on SEC
8-K 7/28/2026 View on SEC
425 7/24/2026 View on SEC
425 7/22/2026 View on SEC
425 7/22/2026 View on SEC
8-K 7/22/2026 View on SEC
4 7/17/2026 View on SEC

Company Information

Field Value
Ticker RGEN
Company Name REPLIGEN CORP
CIK 730272
Sector Biological Products, (No Diagnostic Substances)
Industry Large accelerated filer
Exchange Nasdaq
SIC Code 2836
SIC Description Biological Products, (No Diagnostic Substances)
Entity Type operating
Fiscal Year End 1231
State of Incorporation DE
Phone 7814499560